Author: Michael Jannicelli
Eli Lilly’s Omvoh (mirikizumab) beats J&J’s Stelara in head-to-head study
Omvoh, another IL-23 inhibitor, is already FDA approved for UC and is now reporting good results...
Read More
Current research opportunity on IBD and LGB people in the UK
I am currently recruiting for a research study which explores the experience of individuals from...
Read More
A potential non-invasive stool test and novel therapy for endometriosis
Promising findings could lead to the development of a non-invasive stool test and a new therapy...
Read More
Early exposure to antibiotics decreases risk of developing crohn’s disease.
1654×2206 398,8 kB 1654×2206 398,8 kBView attachment 4960View attachment...
Read More
